C. Bulaï Livideanu
Centre National de la Recherche Scientifique(FR)Université Toulouse III - Paul Sabatier(FR)Université Toulouse III - Paul Sabatier(FR)Inserm(FR)Centre de Recherche en Mathématiques de la Décision(FR)Université de Toulouse(FR)Université Fédérale de Toulouse Midi-Pyrénées(FR)Centre Hospitalier Universitaire de Toulouse(FR)Centre de Recherche en Cancérologie de Toulouse(FR)Toulouse School of Economics(FR)Toulouse Mathematics Institute(FR)Laboratoire National de Référence(MA)Hôpital Larrey(FR)Centre d'Étude et de Recherche Travail Organisation Pouvoir(FR)Hôpital Purpan(FR)
Publications by Year
Research Areas
Mast cells and histamine, Urticaria and Related Conditions, Autoimmune Bullous Skin Diseases, Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases
Most-Cited Works
- → A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma(2011)515 cited
- → Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study(2017)120 cited
- → In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells(2012)97 cited
- → Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score ( ABSIS ) and Pemphigus Disease Area Index ( PDAI ) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus(2016)90 cited
- → Large International Validation of ABSIS and PDAI Pemphigus Severity Scores(2018)89 cited
- → ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases